Reply from the author  by Vercauteren, Sven R. et al.
Letters to the Editor 2075
arteriolopathy after discontinuance of cyclosporine in renal allo-
graft. Clin Nephrol 38:1–8, 1992Cyclosporine-induced
4. Mourad G, Velac C, Ribstein J, Mimran A: Long-term improve-
ment in renal function after cyclosporine reduction in renal trans-nephrotoxicity in plant recipients with histologically proven chronic cyclosporine
nephrotoxicity. Transplantation 65:661–666, 1998
autoimmune diseases
Reply from the authorsTo the Editor: By means of a metaanalysis of random-
ized trials with cyclosporine (CsA) in autoimmune dis- To the Editor: Ponticelli and colleagues comment on
eases (ADs), Vercauteren et al concluded that the drug the fact that we included in our meta-analysis concerning
leads to a substantial risk of nephrotoxicity (Kidney Int CsA-induced nephrotoxicity in autoimmune diseases
54:536–545, 1998). (Kidney Int 54:536–545, 1998), studies in which CsA was
Their metaanalysis included studies in which CsA was used at higher doses than 5 mg/kg/day, and that only a
used at higher doses than the 5 mg/kg/day threshold few patients given low dose CsA had a persistent increase
recommended by the dosage guidelines [1]. In only a of serum creatinine of 10 to 33%. To be more specific,
few patients given low-dose CsA (all of whom had rheu- only 5 of the 18 included studies used doses of CsA of
matoid arthritis) was a persistent increase in serum creat- more than 5 mg/kg/day. The ‘few’ patients they refer to
inine of 10 to 33% observed. However, in rheumatoid actually consist of 40% of the total population of CsA
arthritis this slight increase in serum creatinine may sim- treated patients (337 patients out of 852). These patients
ply reflect an increase in muscle mass following restored had rheumatoid arthritis and were treated with low-dose
physical activity. CsA (that is, ,5 mg/kg/day), and this important sub-
The authors also underline that CsA may induce renal group of patients exhibited a rise in serum creatinine of
morphological changes. As histological changes were al- 10 to 30%. Indeed, patients with psoriasis or Crohn’s
ready present at pre-treatment biopsy in some patients, disease treated with CsA had a less pronounced increase
it is difficult to assess the impact of CsA. On the other in serum creatinine levels.
hand, in AD patients, CsA-induced morphological changes Ponticelli et al suggest that the rise in serum creatinine
are not always followed by a progressive loss of renal in rheumatoid arthritis patients simply reflects an in-
function [2]. Moreover, CsA nephropathy may be re- crease in muscle mass due to restored physical activity.
versed by drug withdrawal or a dose reduction in both Three studies in rheumatoid arthritis patients [refs. 47,
AD [1] and renal transplant patients [3, 4]. 50, 60 in our article) in which low dose CsA was used,
We believe that the administration of CsA to AD pa- included a control group treated with azathioprine or
tients is safe provided that two golden rules are adopted: D-penicillamine (the other 4 studies were placebo-con-
(a) the dose should never exceed 5 mg/kg/day; (b) the trolled). In these three studies, CsA was therapeutically
dose should be reduced if, in two determinations at two- as effective as azathioprine or D-penicillamine, hence
week intervals, serum creatinine increases to 30% above leading to the same degree of restored physical activity.
baseline, and discontinued if creatinine increases $50%. Yet, the CsA treated groups exhibited a rise of serum
Whenever these recommendations are followed, the risk creatinine between 22 and 30%, whereas the azathio-
of irreversible and progressive renal dysfunction in AD prine or D-penicillamine treated control groups had no
patients is at most minimal. rise at all. Suggesting that this ‘slight’ increase in serum
creatinine is due to the restored physical activity is there-Claudio Ponticelli, Aldo F. Finzi,
and Gianfranco Ferraccioli fore rather simplistic. As already mentioned in our arti-
IRCCS, Ospedale Maggiore and University of Milan; cle, this higher increase in serum creatinine in patients
University of Udine, Milan and Udine, Italy
with rheumatoid arthritis is probably due to the potentia-
tion of the nephrotoxic effects of CsA by NSAIDs, which
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dose CsA. We agree that these renal lesions of interstitial tion, and a decrease in oxygen demand in the medulla [3].
In addition, adenosine also appears to decrease sodiumfibrosis and tubular atrophy are not necessarily followed
by a progressive loss of renal function after a treatment chloride transport in the thick ascending limb of Henle’s
of one year with CsA. However, the results of long-term loop [3] as well as to increase blood flow to the medulla
studies [refs. 69, 70, 85], that is, an increase of interstitial by dilating the vasa recta (abstract; Clin Res 36:627A,
fibrosis as a function of time, clearly indicate the progres- 1988). Adenosine administration results in a significant
sive nature of CsA-induced nephrotoxicity. increase in medullary PO2 (in conjunction with a de-
Ponticelli and colleagues state that CsA nephropathy crease in cortical PO2) [5].
is reversible after drug withdrawal. As we discussed, the Thus, I would offer an alternative interpretation to
functional impairment was reversible after withdrawal the observations by Erley et al. While adenosine unques-
of CsA, complete in six studies, but only partial in seven tionably decreases renal function (renal blood flow, glo-
studies. However, follow-up studies after withdrawal merular filtration rate, and reabsorption), this may con-
clearly show that a subgroup of patients still has in- stitute a protective effect, preserving renal viability and
creased levels of serum creatinine 20 to 24 months after assuring better renal function after ischemic insult to the
cessation of the drug [refs. 57 and 64]. Moreover, the kidneys. Oliguria is a sign of a decreased renal function
morphological changes induced by CsA are not revers- which may be interpreted as “acute renal success” [6].
ible and progress in a function of time. Perhaps we should postpone using adenosine antagonists
We agree that short-term treatment of CsA according in the clinical setting in question until further studies on
to the dosage guidelines has an acceptable risk of pro- high-risk patients reveal the truth.
gressive renal dysfunction, but we strongly fear that long-
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1976To the Editor: The interesting and impeccably de-
signed study by Erley et al convincingly demonstrates
the role of adenosine and adenosine receptors in renal Reply from the authors
function [1]. However, their tentative conclusion, that
To the Editor: We express concern about the interpre-adenosine antagonists would be effective in preventing
tation and “tentative conclusion” of our paper, in whichrenal impairment following radiocontrast-medium ad-
we recommend the use of adenosine receptor antagonistsministration is not justified by the study and may be
in the prevention of renal functional impairment followingwrong. There is a fundamental difference between renal
administration of radiocontrast media, especially in thefunction and renal viability. Adenosine constricts pre-
presence of additional risk factors [1]. Instead, Gelmanglomerular vessels and dilates post-glomerular vessels
and Sadovnikoff present an alternative interpretation of(via A1 and A2 receptors, respectively) [2–5]. This re-
our findings, based upon an assumption of a “fundamentalsults in a significant decrease in intra-glomerular pres-
difference between renal function and renal viability.”sure and a decrease in glomerular filtration rate. This is
The authors argue that a decline in renal function wouldexactly what the authors observed. However, a decrease
represent an “acute renal success,” as termed by Thurauin glomerular filtration would result in a decrease in solute
and Boylan [2]. In this context, however, we feel thatdelivery to the tubulae, a decrease in the tubular reabsorp-
this represents an incomplete interpretation of the renal
response to tubular injury, since Thurau and Boylan
described “acute renal success” as a conservation of sys- 1999 by the International Society of Nephrology
